[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Abingdon Health Plc LSE:ABDX London Ordinary Share GB00BLF79J41 ORD 0.025P
  Price Change % Change Share Price Shares Traded Last Trade
  -10.00 -26.32% 28.00 2,657,949 10:18:22
Bid Price Offer Price High Price Low Price Open Price
27.00 29.00 30.50 26.50 29.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 27
Last Trade Time Trade Type Trade Size Trade Price Currency
10:19:00 O 10,000 28.47 GBX

Abingdon Health (ABDX) Latest News (8)

More Abingdon Health News
Abingdon Health Investors    Abingdon Health Takeover Rumours

Abingdon Health (ABDX) Discussions and Chat

Abingdon Health Forums and Chat

Date Time Title Posts
01/12/202110:16Abingdon Health: Lateral Flow Diagnostics1,171
05/11/202110:09freeFor all rampngFree 60

Add a New Thread

Abingdon Health (ABDX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:18:2427.8510,7572,995.82O
10:18:1627.8517,9324,994.06O
10:12:4127.851,034287.97O
10:10:3927.7717,9634,988.33O
10:07:5927.5110,0002,751.00O
View all Abingdon Health trades in real-time

Abingdon Health (ABDX) Top Chat Posts

DateSubject
01/12/2021
08:20
Abingdon Health Daily Update: Abingdon Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ABDX. The last closing price for Abingdon Health was 38p.
Abingdon Health Plc has a 4 week average price of 26.50p and a 12 week average price of 26.50p.
The 1 year high share price is 133.50p while the 1 year low share price is currently 26p.
There are currently 95,699,114 shares in issue and the average daily traded volume is 847,031 shares. The market capitalisation of Abingdon Health Plc is £27,274,247.49.
01/12/2021
08:34
pwhite73: volsung 18 Nov - "Bought a few more at 37.8p Mind you the lesson seems to be sell ABDX on the spikes lol" The lesson seems to be you're not actually learning anything volsung. Told you to avoid ABDX and AVCT.
01/12/2021
07:33
columbarius: Lots of warnings about this. Like on the ODX boards there are too many useless investors spouting nonsense on this thread. columbarius - 15 Sep 2021 - 17:12:16 - 574 of 1143 I think it obvious they need cash. How many times with aim companies have we seen a share price jump then decline into a placing as insiders benefit from knowledge of the placing price.
04/11/2021
14:56
amd75: Why share price is dropping ? Any idea guys
21/10/2021
13:22
bamboo2: eddy, I would chill out. Don't let others' views depress you. They are guilty of bias in talking their own book. Ask yourself, why would someone spend time making up negative stories? I can guarantee they are not doing it for free! They are trying to influence the share price by creating a climate of fear. Posts don't even need to contain any facts to create negativity. Jaks post is partly true, but leaves out the main reason why a large amount of capital was spent, ie a new factory was built, and an existing one upgraded. In fact the upgrade was planned long before covid, and was the main reason for the capital raise and listing. Vatic is just around the corner. Changes to the requirements for LFT's are due tomorrow, things could then get much more interesting. Whenever someone posts something negative, just copy and past this one below it!
06/10/2021
13:03
monte1: To correct a few inaccuracies; 1. Agreed no need for an RNS because although an agreement exists between Vatican/abdx, this would only become material when meaningful manufactured volume has been ordered under the contract. 2. The test has been approved currently for professional use only. A variation of the test is under development for home use which, if approved, will cater to a much increased market place. 3. The DHSC have never stated that the test kits supplied in 2020 do not work. They took delivery and have been using the tests. Their supply has been caught up in allegations of ‘preferential treatment’ granted to abdx by the purchasers which abdx have disputed in detail. This will form part of the GLP instigated judicial review. The DHSC contract provided the right to cancel by 25/12/20 if the tests were not by that time approved for home use. They weren’t and as a result only 1m of a potential 10m order was called off and delivered under the contract which, in any event, expired in Feb 21.
06/10/2021
07:47
pwhite73: The Abingdon/Vatic story is completely bogus. US regulators are much tougher against this kind of behaviour. At the start of the pandemic the SEC suspended several companies including SCworx for putting out questionable orders to boost the share price. https://seekingalpha.com/news/3563088-sec-suspends-trading-in-scworx-over-covidminus-19-test-issue "The SEC has halted trading in SCWorx (WORX) in apparent response to concerns over its previously announced multimillion-test order for COVID-19 blood tests. On April 13, the company announced that it received an order for 2M tests from virtual healthcare network Rethink My Healthcare with a provision for additional orders for 2M tests per week for 23 weeks, an order it confirmed on April 17 after short seller Hindenburg Research published a report questioning its veracity."
22/9/2021
19:10
jaforsadi: Abdx will outshine odx and avct tomorrow. Thats fact. Mainly due to the fact that mcap of abdx is 45m compared to odx which is 96m and avct which is already an eye wayering 319m.Abdx is the one to jump on
15/9/2021
17:21
johncraven2: So what price is the placing? BR is saying 10p. They have to satisfy the IPO holders, allowing them to average down big. Otherwise, the price will plummet a lot more when IPO holders start dumping in 3 months time. Either way, it does not bode well for the share price. It will be difficult to get enough to survive for the next six months. Could be the shortest IPO ever, as administration is clearly in play now. No contract.
25/8/2021
10:02
bmwman3: Credit to joshholdforgold on LSE Share price forecastshare price forecastAssumptions: Enterprise Value = 12x gross profit for non-covid related revenue.Enterprise Value = 6x gross profit for covid related revenue. Non covid revenue = £3.5m H1 2021FY2021 Rev = £7mGross Profit Margin 40%GP = £2.7mFactor x12EV=£32.4mAntibody testrevenue = £33 x margin x sales Gross profit margin (est.) 40%Sales (est.) = 1m/year GP = £13.2mFactor x6EV=£79mNow my projections for the lateral flow test sales relies on my firm belief that AVCT will in the next few weeks receive Home Ise Authorisation for their best in class test. At this point their manufacturing agreement with ABDX will kick in and we can expect orders of 4m tests per month. AVCT test revenue = £5 x margin x sales Gross profit margin (est.) 20%Sales (est.) = 48m/year GP = £46mFactor x6EV=£276mWithout any provision for sales of Abingdon's own covid products we reach a the following valuations:Without AVCT sales:£111.4m = £1.15 per shareWith AVCT sales:£387.4m = £3.99 per share
24/8/2021
07:47
garth: NYB, Thanks for clarifying. On that timescale I expect interesting times in between and some volatility here. But a share price at ABDX north of where it is now. GLH. G.
Abingdon Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ABDX
Abingdon H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211201 10:34:19